Singapore: Eisai's South Korean sales subsidiary has received approval from the regulatory authorities in South Korea to...
Singapore: The former executives and shareholders of Takeda, a leading Japanese firm, have expressed their resentment ov...
Singapore: Swedish specialty pharmaceutical company, Orexo, revealed that that its partner Kyowa Hakko Kirin submitted ...
Singapore: Eisai revealed its preliminary results from a recently completed phase III study of Halaven versus capecitabi...
Singapore: Six current and former female pharmaceutical sales professionals working with Daiichi Sankyo, US, have filed ...
Singapore: Takeda Pharmaceutical's wholly-owned subsidiary, Takeda America, and Envoy Therapeutics have entered into a ...
Singapore: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a...
Singapore: Abbott Japan and Eisai have received approval from Japan's Ministry of Health, Labor and Welfare to market Hu...
Singapore: Daiichi Sankyo's 24-month randomized, double-blind, placebo-controlled multi-center phase III clinical trial ...
Singapore: The Japanese Ministry of Health, Labor and Welfare has approved a new drug application (NDA) of Lotriga granu...
Singapore: Initial results received from the phase III SINGLE (ING114467) study of Shionogi-ViiV Healthcare's investigat...
The fifth edition of the annual BioSpectrum Asia Pacific clinical research organization (CRO) Survey, which is conduct...
Singapore: The Foreign Investment Promotion Board (FIPB) has cleared seven out of the ten investment proposals in the ph...
Singapore: Kyoto University has been granted four patents relating to its basic iPS cell technology, one in Japan and th...
Singapore: Mitsubishi Tanabe Pharma and Daiichi Sankyo have announced that Mitsubishi Tanabe Pharma has received approva...
Singapore: Japan-based Astellas Pharma has submitted a European marketing authorization application to the European Medi...
Singapore: Daiichi Sankyo has submitted a supplemental new drug application to Japan's Ministry of Health, Labor and Wel...
Singapore: Tokyo-based Astellas, a pharmaceutical company, is investing $140 million to locate its headquarters for the ...
